The selling is concentrated in two large holders (Barclays, Citigroup) who together trimmed ~$9.4M. Monitor upcoming 10-Q for any fundamental deterioration that may have prompted the reduction. The absence of insider buying weakens the bullish case from the small buyer cluster.
ABUS drugs
ABUS drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $3.66entry
- T+1 · 8d ago +1.78%α −0.59% · $3.72
- T+5 · 4d ago +11.90%α +9.31% · $4.09
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Institutional activity in ABUS during 2026-Q3 was mixed but skewed bearish: two small asset managers added modest positions totaling $149K, while three larger sellers (Citigroup, Barclays, Pictet) trimmed a combined $9.4M. The selling is dominated by Barclays ($8.0M trim) and Citigroup ($1.4M trim), suggesting reduced conviction among major holders. No insider buying corroborates the institutional moves.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$9.3M
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Principal Financial Group | ADD | +53.7% | $90.0K | $31.0K |
| Creative Planning | ADD | +40.2% | $416.0K | $118.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Pictet Asset Management Holding | TRIM | -31.6% | Not reported | -$37.0K |
| Citigroup | TRIM | -32.5% | Not reported | -$1.4M |
| Barclays | TRIM | -39.4% | Not reported | -$8.0M |
Key Facts
- 2 buyers added $149K in aggregate; 3 sellers trimmed $9.4M in aggregate
- Barclays trimmed 1.66M shares ($8.0M), the largest sell-side move
- Citigroup trimmed 285.4K shares ($1.4M)
- Pictet trimmed 7.6K shares ($37K)
- Principal Financial Group added 6.6K shares ($31K)
- Creative Planning added 25.0K shares ($118K)
- Insider-institutional confluence score 12/100: no open-market insider buying
Financial Impact
Net institutional selling of $9.3M (sellers $9.4M vs buyers $149K), representing roughly 1.5% of market cap
Risk Factors
- 13F data is 45+ days stale; positions may have changed since quarter-end
- Small buyer cluster ($149K) is negligible relative to seller cluster ($9.4M)
- No insider buying to corroborate institutional accumulation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ABUS-2026-Q3 |
Track record
25 reports on ABUS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Viewing Entry $3.66 settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers